



News Release

FOR IMMEDIATE RELEASE**Media Contacts:**

Olivia Finucane
+44 7881 262476
Olivia.finucane@msd.com

MSD Triumphs at National Awards Ceremony

MSD in the UK named as 'Outstanding Company of the Year' and wins a total of five awards at virtual prestigious Pf Awards

LONDON, March 12, 2021 – MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) announced today that they have been named as 'Outstanding Company of the Year' at the 2021 Pf Awards. In total MSD in the UK won five awards and had ten 'Top Finalists' in a total of nine categories.

The Pf Awards, which are held annually, took place virtually on Thursday evening (March 11) and are the largest pharmaceutical sales and recognition awards in the UK.

For the awards this year, MSD in the UK had 26 employees shortlisted in 20 categories.

In addition to MSD winning 'Outstanding Company of the Year' the following MSD employees were **winners** in the following categories:

Andrew Riley and Annie Hughes - NHS Pathway Award.

Tulsi Pindolia and Freya Grummitt - Innovation in Education - Company.

Adele Marshall was a joint winner of the Future Leaders category.

Rebecca Lewis and Owen Hopley - Winners of Outstanding Teamwork category.

Congratulations also go to ten MSD employees who were '**top finalists**' in the below categories:

Holly Smith and Guy Palmer - Excellence in Marketing Award.

George Jackson and Gorkana Galijas - Innovation Team Award.

James Hargrave and Freya Grummitt - Outstanding Collaboration with the NHS.

Jatinder Manku and Maggi Clough - Outstanding Teamwork.

Debbie Berrios – Silva - Omnichannel Sales Professional.

Neil Mac Donald - Responsive Company Strategy Award category.

Debbie Porter, Executive Director, Specialty Care Business Unit at MSD, said: “As a company we pride ourselves on our people - they are our greatest asset and they all believe in the vision of our company - to save and improve lives. It is their belief and commitment to doing what is best for patients everyday that makes our company what it is, and we are extremely proud to have been named Outstanding Company of the Year.

“I am thrilled that the work of our people has been recognised on this national platform. It is a result of their motivation and determination to succeed by putting patients, and those who care for them at the heart of what we do and we should all be incredibly proud of what all of the finalists and winners have achieved.”

Melanie Hamer, Director of Pf Awards, said:

“In what has been an incredibly difficult year, it fills me with pride at the way the industry has come together, worked tirelessly not only on vaccine development, but in supporting the NHS in the Covid effort and working in partnership to tackle the pandemic and ensure patients, and the public, are still at the heart of everything they do.

This year we adjusted the Pf Awards categories to reflect the immense change in the world and the industry, and I have been incredibly impressed at the high level of entries, finalists, top finalists and, of course, winners. To still be able to celebrate these achievements, despite being in lockdown, and without the traditional black-tie dinner, has been fantastic.

Congratulations to every winner and top finalist for achieving so much in the face of such difficulty. We are proud to honour you and celebrate your achievements. The level of entries from MSD this year were impressive. Well done to their teams for their hard work.”

About MSD

For more than 125 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on [Twitter](#), [Instagram](#), [LinkedIn](#), [YouTube](#) and [Facebook](#).

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2019 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

###